To: All Persons or Entities who purchased Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQCM: KERX) stock prior to June 28, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the Keryx merger. Keryx will be sold to Akebia Therapeutics, Inc. (“Akebia”) (NASDAQ GM: AKBA) Under the terms of the transaction, Keryx shareholders will receive 0.37433 common shares of Akebia for each share of Keryx they own. To learn more about the KERX merger and your rights, go to: http://www.zlk.com/mna/keryx-biopharmaceuticals-inc-2 or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Keryx breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Akebia is underpaying for Keryx shares, thus unlawfully harming Keryx shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.